Vanessa Stadlbauer-Köllner | The gut-liver axis as a novel therapeutic target in chronic liver disease

Liver cirrhosis is an increasingly common disease with high rates of complications, leading to high burden of disease for patients, their relatives and the health care system. Liver cirrhosis is associated with changes in the structure and function of the microbiome (dysbiosis) at several body sites and increased gut permeability, resulting in the translocation of bacterial products into the circulation. This leads to inflammation and as a result of ongoing inflammation to immune dysfunction. Therefore, strategies to revert dysbiosis in liver cirrhosis are promising new approaches to improve health in cirrhosis.